Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Clinical and Translational Oncology
Published in: Clinical and Translational Oncology 12/2016

Open Access 01-12-2016 | Clinical Guides in Oncology

SEOM Clinical Guideline of fertility preservation and reproduction in cancer patients (2016)

Authors: M. Muñoz, A. Santaballa, M. A. Seguí, C. Beato, S. de la Cruz, J. Espinosa, P. J. Fonseca, J. Perez, T. Quintanar, A. Blasco

Published in: Clinical and Translational Oncology | Issue 12/2016

Login to get access

Abstract

Chemotherapy and radiotherapy often result in reduced fertility in cancer patients. With increasing survival rates, fertility is an important quality-of-life concern for many young cancer patients. Around 70–75% of young cancer survivors are interested in parenthood but the numbers of patients who access fertility preservation techniques prior to treatment are significantly lower. Moreover, despite existing guidelines, healthcare professionals do not address fertility preservation issues adequately. There is a critical need for improvements in clinical care to ensure patients are well informed about infertility risks and fertility preservation options and to support them in their reproductive decision-making prior to cancer treatment.
Literature
1.
Bleyer A, Viny A, Barr R. Introduction. In: Cancer epidemiology in older adolescents and young adults 15 to 29 years of age, including SEER incidence and survival: 1975–2000. National Cancer Institute, NIH Pub. No. 06-5767, National Institutes of Health, Bethesda; 2006. p. 1.
2.
Ferlay J, Shin H, Bray F, Forman D, Mathers C, Parkin DM. GLOBOCAN 2008 v1.2, Cancer Incidence and Mortality Worldwide: IARC Cancer Base No. 10. International Agency for Research on Cancer, Lyon, France; 2012.
3.
Kenney LB, Cohen L, Shnorhavoriab M, Metzger M, Lockart B, Hijiya N, et al. Male reproductive health after childhood, adolescent, and young adult cancers: a report from the Children’s Oncology Group. J Clin Oncol. 2012;30:3408–16.CrossRefPubMedPubMedCentral
4.
Metzger ML, Meacham L, Patterson B, Casillas J, Constine L, Hijiya N, et al. Female reproductive health after childhood, adolescent, and young adult cancers: guidelines for the assessment and management of female reproductive complications. J Clin Oncol. 2013;31:1239–47.CrossRefPubMedPubMedCentral
5.
Goossens J, Delbaere I, Van Lancker A, Beeckman D, Verhaeghe S, Van Hecke A. Cancer patients’ and professional caregivers’ needs, preferences and factors associated with receiving and providing fertility-related information: a mixed methods systematic review. Int J Nurs Stud. 2014;51:300–19.CrossRefPubMed
6.
Font-Gonzalez A, Mulder RL, Loeffen EA, Byrne J, van Dulmen-den Broeder E, van den Heuvel-Eibrink MM, et al. Fertility preservation in children, adolescents, and young adults with cancer: quality of clinical practice guidelines and variations in recommendations. Cancer. 2016;122(14):2216–23.CrossRefPubMed
7.
Rodriguez-Wallberg KA, Oktay K. Fertility preservation medicine: options for young adults and children with cancer. J Pediatr Hematol Oncol. 2010;32(5):390–6.CrossRefPubMed
8.
Kesic V, Rodolakis A, Denschlag D, Schneider A, Morice P, Amant F, et al. Fertility preserving management in gynecologic cancer patients: the need for centralization. Int J Gynecol Cancer. 2010;20(9):1613–9.PubMed
9.
Schover LR, van der Kaaij M, van Dorst E, Creutzberg C, Huyghe E, Kiserud CE. Sexual dysfunction and infertility as late effects of cancer treatment. Eur J Cancer. 2014;12(Suppl):41–53.CrossRef
10.
Chow EJ, Stratton KL, Leisenring WM, Oeffinger KC, Sklar CA, Donaldson SS, et al. Pregnancy after chemotherapy in male and female survivors of childhood cancer treated between 1970 and 1999: a report from the Childhood Cancer Survivor Study cohort. Lancet Oncol. 2016;17(5):567–76.CrossRefPubMed
11.
12.
Llarena NC, Estevez SL, Tucker SL, Jeruss JS. Impact of fertility concerns on tamoxifen initiation and persistence. J Natl Cancer Inst. 2015;107:djv202.CrossRefPubMed
13.
Thomas-Teinturies C, Setcheou-Allodji R, Svetlova E, Frey MA, Oberlin O, Millischer AE, et al. Ovarian reserve after treatment with alkylating agents during childhood. Hum Reprod. 2015;30:1437–46.CrossRef
14.
Picton HM, Wyns C, Anderson RA, Goossens E, Jahnukainen K, Kliesch S, et al. An European perspective on testicular tissue cryopreservation for fertility preservation in prepubertal and adolescent boys. Hum Reprod. 2015;30:2463–76.CrossRefPubMed
15.
16.
Peccatori F, Azim HA Jr, Orecchia R, Hoekstra HJ, Pavlidis N, Kesic V, et al. Cancer, pregnancy and fertility: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow up. Ann Oncol. 2013;24:160–70.CrossRef
17.
Loren AW, Mangu PB, Beck LN, Brennan L, Magdalinski AJ, Partridge AH, et al. Fertility preservation for patients with cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol. 2013;19:2500–10.CrossRef
18.
Tournaye H, Dohle GR, Barratt C. Fertility preservation options for men and women with cancer. Lancet. 2014;384:1295–301.CrossRefPubMed
19.
Hourvitz A, Goldschlag DE, Davis OK, Gosden LV, Palermo GD, Rosenwaks Z. Intracytoplasmic sperm injection (ICSI) using cryopreserved sperm from men with malignant neoplasm yields high pregnancy rates. Fertil Steril. 2008;90:557–63.CrossRefPubMed
20.
Salama M, Winkler K, Murach KF, Seeber B, Ziehr SC, Wildt L. Female fertility loss and preservation: threats and opportunities. Ann Oncol. 2013;24(3):598–608.CrossRefPubMed
21.
Angarita AM, Johnson CA, Fader AN, Christianson MS. Fertility preservation: a key survivorship issue for young women with cancer. Front Oncol. 2016;6:1–10.CrossRef
22.
Dolmans MM, Hollanders de Ouderaen S, Demylle D, Pirard C. Utilization rates and results of long-term embryo cryopreservation before gonadotoxic treatment. J Assist Reprod Genet. 2015;32(8):1233–7.CrossRefPubMedPubMedCentral
23.
Cobo A, Diaz C. Clinical application of oocyte vitrification: a systematic review and meta-analysis of randomized controlled trials. Fertil Steril. 2011;96:277–85.CrossRefPubMed
24.
Cobo A, Meseguer M, Remohi J, Pellicer A. Use of cryo-banked oocytes in an ovum donation programme: a prospective, randomized, controlled, clinical trial. Hum Reprod. 2010;25(9):2239–46.CrossRefPubMed
25.
Donnez J, Dolmans MM. Ovarian cortex transplantation: 60 reported live births brings the success and worldwide expansion of the technique towards routine clinical practice. J Assist Reprod Genet. 2015;32(8):1167–70.CrossRefPubMedPubMedCentral
26.
Hickman LC, Valentine LN, Falcone T. Preservation of gonadal function in women undergoing chemotherapy: a review of the potential role for gonadotropin-releasing hormone agonists. Am J Obstet Gynecol. 2016;215(4):415–22.CrossRefPubMed
27.
Demeestere I, Brice P, Peccatori FA, Kentos A, Dupuis J, Zachee P, et al. No Evidence for the benefit of gonadotropin-releasing hormone agonist in preserving ovarian function and fertility in lymphoma survivors treated with chemotherapy: final long-term report of a prospective randomized trial. J Clin Oncol. 2016;34(22):2568-74.CrossRefPubMed
28.
29.
Practice Committee ISFP, Kim SS, Donnez J, Barri P, Pellicer A, Patrizio P, Rosenwaks Z, et al. Recommendations for fertility preservation in patients with lymphoma, leukemia, and breast cancer. J Assist Reprod Genet. 2012;29(6):465–8.CrossRef
30.
Lambertini M, Ceppi M, Poggio F, Peccatori FA, Azim HA Jr, Ugolini D, et al. Ovarian suppression using luteinizing hormone-releasing hormone agonists during chemotherapy to preserve ovarian function and fertility of breast cancer patients: a meta-analysis of randomized studies. Ann Oncol. 2015;26:2408–19.CrossRefPubMed
31.
Feichtinger M, Rodriguez-Wallberg KA. Fertility preservation in women with cervical, endometrial or ovarian cancers. Gynecol Oncol Res Pract. 2016;27(3):8.CrossRef
32.
Fastrez M, Houba C, Vandromme J, Rozenberg S. Fertility-sparing management of gynecological cancers. Maturitas. 2015;82(2):141–5.CrossRefPubMed
33.
Jadoul P, Dolmans MM, Donnez J. Fertility preservation in girls during childhood: is it feasible, efficient and safe and to whom should it be proposed? Hum Reprod Update. 2010;16:617–30.CrossRefPubMed
34.
Hussein AA, Tran ND, Smith JF. Fertility preservation for boys and adolescents facing sterilizing medical therapy. Transl Androl Urol. 2014;3(4):382–90.PubMedPubMedCentral
35.
Gawade PL, Oeffinger KC, Sklar CA, Green DM, Krull KR, Chemaitilly W, et al. Lifestyle, distress, and pregnancy outcomes in the Childhood Cancer Survivor Study cohort. Am J Obstet Gynecol. 2015;212(1):47.CrossRefPubMed
36.
Tarín JJ, García-Pérez MA, Cano A. Obstetric and offspring risks of women’s morbid conditions linked to prior anticancer treatments. Reprod Biol Endocrinol. 2016;14(1):37.CrossRefPubMedPubMedCentral
37.
Metadata
Title
SEOM Clinical Guideline of fertility preservation and reproduction in cancer patients (2016)
Authors
M. Muñoz
A. Santaballa
M. A. Seguí
C. Beato
S. de la Cruz
J. Espinosa
P. J. Fonseca
J. Perez
T. Quintanar
A. Blasco
Publication date
01-12-2016
Publisher
Springer International Publishing
Published in
Clinical and Translational Oncology / Issue 12/2016
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-016-1587-9

Other articles of this Issue 12/2016

Clinical and Translational Oncology 12/2016 Go to the issue

Clinical Guides in Oncology

SEOM Clinical Guideline for the treatment of pancreatic cancer (2016)

Clinical Guides in Oncology

SEOM Clinical Guideline for treatment of muscle-invasive and metastatic urothelial bladder cancer (2016)

Clinical Guides in Oncology

SEOM Clinical Guideline of localized rectal cancer (2016)

Clinical Guides in Oncology

SEOM Clinical Guideline for bone metastases from solid tumours (2016)

Clinical Guides in Oncology

SEOM clinical guidelines for the management of germ cell testicular cancer (2016)

Clinical Guides in Oncology

SEOM Clinical Guideline for gastrointestinal sarcomas (GIST) (2016)
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits